Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (West), Mumbai, 400056, India.
Department of Biological Sciences, Sunandan Divatia School of Science, SVKM's NMIMS (Deemed-to-be University), Vile Parle (West), Mumbai, India.
Med Oncol. 2024 May 20;41(6):161. doi: 10.1007/s12032-024-02382-w.
Despite decades of basic and clinical research and trials of promising new therapies, cancer remains a major cause of morbidity and mortality due to the emergence of drug resistance to anticancer drugs. These resistance events have a very well-understood underlying mechanism, and their therapeutic relevance has long been recognized. Thus, drug resistance continues to be a major obstacle to providing cancer patients with the intended "cure". PAQR4 (Progestin and AdipoQ Receptor Family Member 4) gene is a recently identified novel protein-coding gene associated with various human cancers and acts through different signaling pathways. PAQR4 has a significant influence on multiple proteins that may regulate various gene expressions and may develop chemoresistance. This review discusses the roles of PAQR4 in tumor immunity, carcinogenesis, and chemoresistance. This paper is the first review, discussing PAQR4 in the pathogenesis of cancer. The review further explores the PAQR4 as a potential target in various malignancies.
尽管经过几十年的基础和临床研究以及对有前途的新疗法的试验，但由于抗癌药物耐药性的出现，癌症仍然是发病率和死亡率的主要原因。这些耐药事件有一个非常明确的潜在机制，其治疗相关性早已得到认可。因此，耐药性仍然是为癌症患者提供预期“治愈”的主要障碍。PAQR4（孕激素和脂联素 Q 受体家族成员 4）基因是最近发现的与多种人类癌症相关的新型蛋白编码基因，通过不同的信号通路发挥作用。PAQR4 对可能调节各种基因表达并可能产生化疗耐药性的多种蛋白质有重大影响。本综述讨论了 PAQR4 在肿瘤免疫、致癌和化疗耐药性中的作用。本文是第一篇综述，讨论了 PAQR4 在癌症发病机制中的作用。该综述进一步探讨了 PAQR4 作为各种恶性肿瘤的潜在靶点。
